Brentuximab vedotin (Adcetris®) is accepted for restricted use within NHS Scotland

Source:
Scottish Medicines Consortium - SMC
Publisher:
Scottish Medicines Consortium
Publication date:
13 January 2020

Abstract

Brentuximab vedotin is accepted for use in NHS Scotland for adult CD30+ cutaneous T-cell lymphoma (CTCL) after one prior systemic therapy. Restricted to use in advanced CTCL (mycosis fungoides stage IIB, primary cutaneous anaplastic large cell lymphoma or Sézary Syndrome).